CLEO DIAGNOSTICS LTD — Share Issue/Capital Change 2025

Dec 28, 2025

ASX Announcement

ASX: COV

29 December 2025

==> picture [62 x 70] intentionally omitted <==

NOTICE UNDER SECTION 708A(5)(E) OF THE CORPORATIONS ACT 2001

• (a) The Company has issued 8,362,084 fully paid ordinary shares (Shares) in the Company.

• (b) The Shares were issued without disclosure to investors under Part 6D.2 of the Corporations Act.

• (c)

• As at the date of this notice, the Company has complied with:

• the provisions of Chapter 2M of the Corporations Act, as they apply to the Company; and

• sections 674 and 674A of the Corporation Act.

• (d) As at the date of this notice, there is no 'excluded information' (within the meaning of sections 708A(7) and 708A(8) of the Corporations Act) required to be disclosed under section 708A(6)(e) of the Corporations Act.

Released with the authority of the Board.

==> picture [116 x 63] intentionally omitted <==

Pauline Moffatt Company Secretary

Cleo Diagnostics Ltd ASX: COV Level 2, 480 Collins Street, Melbourne, VIC, 3000 ACN 655 717 169 T +61 3 9614 0600 E office@cleodx.com Directors Chair and Non-Executive Director Adrien Wing Chief Executive Officer and Executive Director Dr Richard Allman Chief Scientific Officer and Executive Director Dr Andrew Stephens Non-Executive Director and Lead Medical Advisor Professor Tom Jobling Non-Executive Director Lucinda Nolan

cleodx.com